| 1.
論文(リポジトリ) |
論文(リポジトリ)
|
小川, 淳 ; 片岡, 哲 ; 浅見, 恵子 ; 内海, 治郎 ; 笹崎, 義博
|
||||
| 2.
論文(リポジトリ) |
論文(リポジトリ)
|
小野, 徹 ; 金子, 恭士 ; 武田, 幸彦 ; 岡野, 篤夫 ; 土川, 幸三 ; 加藤, 譲治 ; 内海, 治郎 ; 長谷川, 聡
|
||||
| 3.
論文(リポジトリ) |
論文(リポジトリ)
|
小川, 淳 ; 片岡, 哲 ; 浅見, 恵子 ; 内海, 治郎 ; 笹崎, 義博
|
||||
| 4.
論文(リポジトリ) |
論文(リポジトリ)
|
内海, 治郎
概要:
For improving the QOL of patients in childhood cancer, it should be emphasized that those patients are always growing. Since the goal of the treatment of childhood cancer is cure of growing patients, the development of the treatment
…
with minimal sequelae would be essential. In the present symposium, I summarized 3 important points as follows : 1) present status of central nervus system prophyraxis that often cause late developmental sequelae in the treatment of acute lymphoblastic leukemia (ALL). 2) short stature after completion of the treatment of ALL. 3) the role of main doctor and family in the treatment of dying patients. Finally, the important role of main doctor in the proceeding to a high school, employment, and marriage of cured patients, was emphasized.
続きを見る
|
||||
| 5.
論文(リポジトリ) |
論文(リポジトリ)
|
笹崎, 義博 ; 浅見, 恵子 ; 内海, 治郎
|
||||
| 6.
論文(リポジトリ) |
論文(リポジトリ)
|
張, 高明 ; 横山, 晶 ; 林, 直樹 ; 筒井, 一哉 ; 栗田, 雄三 ; 浅見, 恵子 ; 笹崎, 義博 ; 内海, 治郎 ; 牧野, 春彦 ; 佐野, 宗明 ; 本間, 滋 ; 高橋, 威 ; 北村, 康男 ; 渡辺, 学 ; 小松原, 秀一 ; 坂田, 安之輔
|
||||
| 7.
論文(リポジトリ) |
論文(リポジトリ)
|
田中, 彰 ; 土持, 眞 ; 又賀, 泉 ; 柴崎, 浩一 ; 浅見, 恵子 ; 内海, 治郎
|
||||
| 8.
論文(リポジトリ) |
論文(リポジトリ)
|
水野, 祐子 ; 桜井, 友子 ; 中川, 利子 ; 佐藤, 正之 ; 村川, 英三 ; 笹崎, 義博 ; 浅見, 恵子 ; 内海, 治郎
|
||||
| 9.
論文(リポジトリ) |
論文(リポジトリ)
|
内海, 治郎 ; 浅見, 恵子 ; 笹崎, 義弘
概要:
92 patients with acute lymphocytic leukemia （ALL）, 29 patients with acute nonlymphocytic leukemia （ANLL）, and 6 patients
…
with chronic myelogenous leukemia （CML） admitted to the Department of Pediatrics, Niigata Cancer Center Hospital between Jan. 1961 and Dec. 1988 are reviewed in this study. From 1981 to 1985, a complete remission in 96% of patients with ALL could be archived by remission induction therapies according to risk factors. The rate of continuous complete remission was 74% at 3 years and 57% at 5 years after a complete remission of the bone marrow. Cessation of maintenance therapies in 21 patients with ALL, who began remission induction therapies from 1977 to 1985 and continuous complete remission for more than 3 years, was undertaken. After cessation of therapies, the rate of continuous complete remission was 86% at 3 years and relapses were not seen for more than 3 years. Relapses occured in 4 patients from 2 to 26 months after cessation of therapies. The sites of the relapses were 3 case of bone marrow, and 1 case of bone marrow/CNS. Compared with ALL, the results of remission induction and maintenance therapies in childhood ANLL and CML are not as positive and bone marrow transplantation must be introduced in pediatrics.
続きを見る
|
||||
| 10.
論文(リポジトリ) |
論文(リポジトリ)
|
岩渕, 眞 ; 大沢, 義弘 ; 内山, 昌則 ; 松田, 由紀夫 ; 内藤, 真一 ; 広田, 雅行 ; 内藤, 万砂文 ; 近藤, 公男 ; 内海, 治郎 ; 浅見, 恵子 ; 笹崎, 義博 ; 小田, 良彦 ; 佐藤, 雅久
概要:
Twenty-two pediatric patients with a stage IV-A or IV-B neuroblastoma have been treated with multimodal therapy consisti
…
ng of intensive chemotherapy and surgery at Niigata University Hospital since 1985. The patients first received six cyclic courses of intensive chemotherapy ［regimen A_1］, consisting of cyclophosphamide ［1,200mg/m^2］, vincristine ［1.5mg/m^2], tetrahydropyranyl adriamycin ［pyrarubicin 40mg/m^2］, and cisplatin ［90mg/m^2］. Primary tumors and involved regional lymph nodes were removed sometime during first six cycles of chemotherapy. After the six cycles of ［Regiment A_1］, patients received alternating treatment with ［Regimen A_2］consisting of cyclophophamide ［1,500mg/m^2］, THP-adriamycin ［50mg/m^2］, cisplatin ［90mg/m^2］, and ［Regimen C］consisting of cyclophosphamide ［1,500mg/m^2］, DTIC ［250mg/m^2］. Two-year survival rate was 59%. Nine patients have now survived with disease free at 2 years after initiation of the treatment （survival rate: 41%）. From the viewpoint of prognosis, the influencing factors are as follows: small round cell type, diploidy, VMA（－）, NSE more than 100ng/ml, N-myc over 8 times of normal value.
続きを見る
|
